SEATTLE, WA--(Marketwired - May 21, 2013) - Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, is sponsoring two screenings of the new film Decoding Annie Parker at the Seattle International Film Festival on June 6 and 8, 2013.

Based on true events, Decoding Annie Parker follows a 15-year war waged on both scientific and emotional fronts by a pair of women demonstrating extreme bravery under pressure. Annie Parker (Samantha Morton) is on intimate terms with breast cancer, having watched both her mother and sister succumb to it. When she herself is diagnosed with the disease, she struggles to hold her family together, displaying a force of spirit that belies the odds. Elsewhere, geneticist Mary-Claire King (Helen Hunt) is researching the idea of an undiscovered link between DNA and cancer, a process that finds her scrambling for both funding and the support of her disbelieving colleagues. How the paths of these two women intersect is funny, irreverent and heartwarming. Director Steven Bernstein's feature debut deftly balances the seriousness of the situation with the all-too-human response, finding unpredictable grace notes of beauty and wit during even the darkest of times. Featuring stellar performances by Morton, Hunt and a first-rate supporting cast, Bernstein's film pays ample tribute to one of the most important scientific discoveries of the 20th century as well as the people forever changed in its wake.

Dr. Steven Quay, chairman, CEO & president of Atossa Genetics, stated, "We are honored to sponsor Decoding Annie Parker, a work that celebrates Dr. Mary-Claire King's laboratory at the University of Washington and its mission to further understand the role of genetics in breast cancer. It is a mission we all applaud at Atossa Genetics, which is focused on assessing breast cancer risk with our recently launched ForeCYTE Breast Health Test. We are also dedicated to the prevention of breast cancer through the development and commercialization of an investigative intraductal therapy approach to treat precancerous abnormalities, including ductal carcinoma in situ."

"The Seattle International Film Festival is proud to partner with Atossa Genetics in honoring Dr. King's discovery of the link between DNA and breast cancer," said Mary Bacarella, Managing Director, Seattle International Film Festival. "Decoding Annie Parker is a film that pays tribute to one of the most important scientific discoveries of the 20th century. Dr. King's BRCA test and Atossa Genetics' ForeCYTE Breast Health Test are changing the future of breast cancer detection and prevention. SIFF is extremely proud to play a role in raising public awareness of this incredible work."

More information about Decoding Annie Parker is available at and

About the Seattle International Film Festival

Founded in 1976, the Seattle International Film Festival (SIFF) creates experiences that bring people together to discover extraordinary films from around the world with the Seattle International Film Festival, SIFF Cinema and FutureWave Education.

Recognized as one of the top film festivals in North America, the Seattle International Film Festival is the largest, most highly attended film festival in the United States reaching more than 150,000 annually. The 25-day festival is renowned for its wide-ranging and eclectic programming presenting over 250 features and 150 short films from over 70 countries each year.

About Atossa Genetics, Inc.

Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, is based in Seattle, WA, and is focused on preventing breast cancer through the commercialization of patented diagnostic medical devices and patented laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.

The National Reference Laboratory for Breast Health (NRLBH), a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington. The NRLBH provides the patented ForeCYTE Breast Health Test, a risk assessment test for women 18 to 73 years of age akin to the Pap Smear, and the ArgusCYTE Breast Health Test, a blood test for recurrence in breast cancer survivors that provides a "liquid biopsy" for circulating breast cancer cells and a tailored treatment plan for patients and their caregivers.

For additional information, please visit You can also view a video about the ForeCYTE test here:

Forward-Looking Statements

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, regulatory clearances, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services, performance of distributors and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its registration statement on Form S-1 filed April 5, 2013, and periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

Contact Information:


Atossa Genetics, Inc.
Chris Destro
Vice President
(O) 800-351-3902
(M) 206-310-2335

MBS Value Partners, LLC (Investors)
Matthew D. Haines
Managing Director
(O) 212-710-9686